Retinitis pigmentosa (RP) is a group of inherited disorders characterized by progressive peripheral vision loss and night vision difficulties (nyctalopia) that can lead to central vision loss.
The prevalence of RP is reported to be approximately 1 in 4000 people worldwide and it affects more than 1,500,000 patients worldwide (Verbakel et al., 2018, Prog Retin Eye Res). The age of onset can vary but RP is usually diagnosed in young adulthood, although it can present anywhere from infancy to the mid-30s to 50s.
Today, there is no effective treatment for this condition.
InFlectisBioScience is developing IFB-088 for the treatment of RP associated to the mutation of Rhodopsin, protein expressed in photoreceptors.